MEXITIL
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEXITIL is an oral small-molecule antiarrhythmic agent approved in 1985 by Boehringer Ingelheim. The drug's specific mechanism of action and approved indications are not documented in available data, but it is formulated as an oral capsule for systemic delivery. This legacy product represents a mature segment of cardiac therapeutics.
LOE Approaching
As loss of exclusivity approaches, the commercial team is likely contracting; roles focus on defending market share against generics rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MEXITIL currently has zero linked job openings, reflecting its mature, declining lifecycle stage. Roles available are primarily in generic defense and market maintenance rather than innovation or growth.
Generic Defense ManagerBrand Manager
Worked on MEXITIL at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.